Investigation to Evaluate PAPILOCARE® Gel Effect on Normalization of Cervix Cytological Alterations Caused by HPV.

HPV Infection Clinical Trial

— PAPILOBS  

Official title:

Investigación clínica Para la evaluación Del Efecto de PAPILOCARE® en la normalización de Las Alteraciones citológicas Del Cuello Del útero Causadas Por el VPH

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04199260
• Other study ID #: PAPILOBS-2017-01
• Status: Completed
• Start date: May 20, 2018
• Est. completion date: February 18, 2021

Study information

• Verified date: August 2021
• Source: Procare Health Iberia S.L.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Observational clinical study, national, multicentric, prospective, non-comparative, with medical device, under application consistent with CE marking, for the evaluation of Papilocare® effectivness in the normalization of cervix cytological abnormalities caused by HPV.

Description:

300 patients will be included in approximately 50 Spanish sites. The study comprehend a maximum of 3 visits. At visit 1, patient's writted informed consent will be collected, patient's selection critera will be checked, and patient's medial history data will be collected. At visit 2, 6 months after the first visit, the primary and secondary objectives will be evaluated. For those patients who finish treatment after 6 months, this will be the final visit. Only in that cases where, by usual clinical practice, the doctor indicates patient should continue under treatment, visit 3, wich will take place 12 months after streatment stars, will be the last visit for the patient under study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 263
• Est. completion date: February 18, 2021
• Est. primary completion date: February 18, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 25 Years and older

Eligibility

Inclusion Criteria:

1. Woman over 25 years, whether or not they have been vaccinated against HPV.

2. Able to read and understand the Patient Information Sheet and the Informed Consent form and accept the participation in the study by signing the Informed Consent form.

3. Patient who comes to a visit with a routine cytological result of ASCUS or LSIL and HPV-positive test, of at most 3 months prior to the start of treatment with Papilocare®.

4. Patient who, under that situation, undergoes a colposcopy and has a concordant result with cytology.

5. Patient who has been prescribed treatment with Papilocare® by medical decision prior to their participation in the study.

Exclusion Criteria:

1. Any situation / alteration / pathology, gynecological or not, which, in medical judgment, does not advise or contraindicate the use of Papilocare®.

2. Women of childbearing age who do not use effective contraceptive methods, pregnant women, suspected pregnancy, desire for the same within the next 6 months or during breastfeeding.

3. Participation in any one clinical trial at present or in the 4 weeks prior to inclusion in the study.

4. Any planned surgery that precludes correct compliance with the guideline.

5. Known allergies to any of the components of Papilocare®.

Related Conditions & MeSH terms

• HPV Infection
• Lesion Cervix
• Papillomavirus Infections

Intervention

Device:
• papilocare vaginal gel
Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution

Locations

Country	Name	City	State
Spain	Hospital General Universitario de Alicante	Alicante
Spain	Clínica Diatros	Barcelona
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona
Spain	Women´s Health Institute	Barcelona
Spain	Gabinete Médico Velázquez	Madrid
Spain	Hospital Clínico San Carlos	Madrid
Spain	Instituto Palacios de Salud y Medicina de la Mujer	Madrid
Spain	MD Anderson	Madrid
Spain	Hospital Quirón Málaga	Málaga

Sponsors (2)

Lead Sponsor	Collaborator
Procare Health Iberia S.L.	Adknoma Health Research

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Evaluate the results of the biopsy (optional)	To assess the effect on biopsies (when available), the percentage of patients who improve and those who maintain the degree of histological alteration have been established at 6 months (and at 12 months if applicable) of the start of treatment.	6 months
Other	Evaluate the results of the biopsy (optional)	To assess the effect on biopsies (when available), the percentage of patients who improve and those who maintain the degree of histological alteration have been established at 6 months (and at 12 months if applicable) of the start of treatment.	12 months if applicable
Primary	Percentage of patient who normalized their cytology with concordant colposcopy.	The percentage of patients with normalization of the cytology with concordant colposcopy, at 6 months, and at 12 months if applicable, has been established as the main variable of the study, in order to assess the degree of normalization of cytological alterations.; Colposcopy concordant with normalized cytology results will be considered those colposcopic findings classified as normal, non-specific or as abnormal grade 1 (minor) according to the definition of the Nomenclature Committee of the International Federation of Cervical and Colposcopic Pathology (IFCPC). accepted at the Rio World Congress, July 5, 2011.	6 months
Primary	Percentage of patient who normalized their cytology with concordant colposcopy.	The percentage of patients with normalization of the cytology with concordant colposcopy, at 6 months, and at 12 months if applicable, has been established as the main variable of the study, in order to assess the degree of normalization of cytological alterations.; Colposcopy concordant with normalized cytology results will be considered those colposcopic findings classified as normal, non-specific or as abnormal grade 1 (minor) according to the definition of the Nomenclature Committee of the International Federation of Cervical and Colposcopic Pathology (IFCPC). accepted at the Rio World Congress, July 5, 2011.	12 months if applicable
Secondary	Percentage of patient who clear partially or completely the presence of HPV	To evaluate the clearance of HPV, the percentage of patients with total or partial clearance of HPV measured by PCR or genetic diagnostic kits that allow the identification of strains at 6 months (and 12 months if applicable) from the start of treatment.	6 months
Secondary	Percentage of patient who clear partially or completely the presence of HPV	To evaluate the clearance of HPV, the percentage of patients with total or partial clearance of HPV measured by PCR or genetic diagnostic kits that allow the identification of strains at 6 months (and 12 months if applicable) from the start of treatment.	12 months if applicable
Secondary	Patient's satisfaction degree with the study treatment	Changes appreciated in the Likert scale at 6 months (and at 12 months if applicable) of the start of treatment will be used to evaluate satisfaction degree with the use of Papilocare gel as treatment.	6 months
Secondary	Patient's satisfaction degree with the study treatment	Changes appreciated in the Likert scale at 6 months (and at 12 months if applicable) of the start of treatment will be used to evaluate satisfaction degree with the use of Papilocare gel as treatment.	12 months if applicable
Secondary	Safety and tolerability of treatment	The incidence, nature and severity of adverse events during the 6 months (or 12 months if applicable) of the duration of the treatment will be used to assess the safety and tolerability of treatment.	6 months
Secondary	Safety and tolerability of treatment	The incidence, nature and severity of adverse events during the 6 months (or 12 months if applicable) of the duration of the treatment will be used to assess the safety and tolerability of treatment.	12 months if applicable